Projects per year
Personal profile
Area of Expertise
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.
Education/Academic qualification
BS in Physics, University of Kerala
MS in Biochemistry, University of Poona
PhD in Biochemistry, University of Poona
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Emerging role of tumor-derived
Chaudhary, P. (PI), Mathew, P. (CoI) & Nandy, R. (CoI)
NCI: National Cancer Institute
1/08/23 → 31/07/25
Project: Research
-
Exosomal-Annexin A2 Promotes Metastasis in Triple-negative Breast Cancer
Chaudhary, P. (PI) & Mathew, P. (CoI)
1/06/17 → 31/05/18
Project: Research
-
Molecular Characterization of NKp44 Ligand on Astrocytes
Mathew, P. (PI)
1/02/17 → 31/01/20
Project: Research
-
Molecular Characterization of NKp44 Ligand on Astrocytes
Mathew, P. (PI) & Mathew, S. (CoI)
NINDS: Neurological Disorders & Stroke
1/02/17 → 31/01/19
Project: Research
-
Molecular Characterization of NKp44 Ligand on Astrocytes
Mathew, P. (PI)
National Institute of Neurological Disorders and Stroke
1/02/17 → 31/01/20
Project: Research
-
Overexpression of LLT1 (CLEC2D) in childhood Acute Lymphoblastic Leukemia (ALL)
Mathew, S., Powers, S. B., Daniel, S., Jose, R., Aryal, S., Bowman, P. & Mathew, P., 1 May 2020, In: Journal of Immunology. 204, 1Research output: Contribution to journal › Meeting Abstract › peer-review
-
Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4
Boles, K. S., Nakajima, H., Colonna, M., Chuang, S. S., Stepp, S. E., Bennett, M., Kumar, V. & Mathew, P. A., 1999, In: Tissue Antigens. 54, 1, p. 27-34 8 p.Research output: Contribution to journal › Article › peer-review
-
Altered expression of LLT1 and CS1 in pediatric Acute Lymphoblastic Leukemia (ALL)
Marrufo, A. M., Mathew, S., Chaudhary, P. & Mathew, P., 1 May 2018, In: Journal of Immunology. 200, 1Research output: Contribution to journal › Meeting Abstract › peer-review
-
Overexpression of LLT1 (CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A interaction
Mathew, S., Chaudhary, P., Powers, S. B., Vishwanatha, J. & Mathew, P., 1 May 2015, In: Oncotarget. 18, 7Research output: Contribution to journal › Meeting Abstract › peer-review
-
Perforin: More than just an effector molecule
Stepp, S. E., Mathew, P. A., Bennett, M., De Saint Basile, G. & Kumar, V., 1 Jun 2000, In: Immunology Today. 21, 6, p. 254-256 3 p.Research output: Contribution to journal › Short survey › peer-review